Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Mouse Homolog of Mutant Wasp Responsible for X-Linked Neutropenia Causes Reduced Myeloid Progenitor Activity but Rather Increased Neutrophil Compartment in Bone Marrow

Masahiro Ikeda, Muneyoshi Futami, MD PhD, Bidisha Chanda, MD PhD, Masayuki Kobayashi, MD PhD, Kiyoko Izawa, PhD, Arinobu Tojo, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139059

Published: 2020

Journal Articles

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Muneyoshi Futami, MD PhD, Keisuke Suzuki, MS, Satomi Kato, BS, Yoshio Tahara, MS, Yoichi Imai, MD PhD, Takayuki Mimura, PhD, Yoshihiro Watanabe, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 2067.

https://doi.org/10.1182/blood-2019-129601

Published: 2019

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

Evaluation of Oncolytic Viral Therapy Combined with or without Artificial Immunoadjuvant Cell Therapy in Immunocompetent Mouse Tumor Models

Weng-Chit Ung, MSc, Muneyoshi Futami, MD PhD, Kota Sato, MDPhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 5793.

https://doi.org/10.1182/blood-2018-99-112789

Published: 2018

Journal Articles

A Novel Mutant Wasp in X-Linked Neutropenia Partially Recapitulates Defective Neutrophil Production through Its Expression in WASP-Deficient NB4 Cells

Masayuki Kobayashi, MD, Bidisha Chanda, MD PhD, Muneyoshi Futami, MD PhD, Mizuho Yamashita, Mitsuhito Hirano, MD, Kazuaki Yokoyama, MD PhD, Yoichi Imai, MDPhD, Eigo Shimizu, Nozomi Yusa, Rui Yamaguchi, PhD, Seiya Imoto, PhD, Satoru Miyano, PhD, Arinobu Tojo, MD PhD

Blood (2017) 130 (Supplement 1): 3560.

https://doi.org/10.1182/blood.V130.Suppl_1.3560.3560

Published: 2017

Journal Articles

Feasibility of a Cell-Based Oncolytic Virotherapy Targeting Bone Marrow Lesions of Multiple Myeloma

Kota Sato, MD, Muneyoshi Futami, MD PhD, Ung Weng Chit, Takafumi Nakamura, MD PhD, Arinobu Tojo, MD PhD

Blood (2016) 128 (22): 4499.

https://doi.org/10.1182/blood.V128.22.4499.4499

Published: 2016

Journal Articles

The G-CSF Receptor Requires Gab2-Mediated Recruitment of the Tyrosine Phosphatase Shp2 to Promote Lyn-Dependent Proliferation.

Muneyoshi Futami, MD, PhD, Quan-Sheng Zhu, MD, PhD, Gen-Sheng Feng, Benjamin Neel, MD, PhD, Seth J. Corey, MD

Blood (2010) 116 (21): 1555.

https://doi.org/10.1182/blood.V116.21.1555.1555

Published: 2010

Journal Articles

RNAi-Mediated Silencing of p190Bcr-Abl Inactivates Stat5 and Cooperates with Imatinib Mesylate and 17-Allylamino-17-Demetoxygeldanamycin in Selective Killing of p190Bcr-Abl-Expressing Leukemia Cells.

Muneyoshi Futami, MD, Toshiyuki Hatano, Yasushi Soda, M.D., Ph.D., Seiichiro Kobayashi, M.D., Ph.D., Makoto Miyagishi, Ph.D., Arinobu Tojo, M.D., Ph.D.

Blood (2007) 110 (11): 2783.

https://doi.org/10.1182/blood.V110.11.2783.2783

Published: 2007

Journal Articles

ShRNA Targeting p190BCR-ABL Successfully Eliminates Ph-ALL Cells with or without ABL Kinase Domain Mutation.

Muneyoshi Futami, MD, Toshiyuki Hatano, Yasushi Soda, M.D., Ph.D., Seiichiro Kobayashi, M.D., Ph.D., Makoto Miyagishi, Ph.D., Arinobu Tojo, M.D., Ph.D.

Blood (2006) 108 (11): 1838.

https://doi.org/10.1182/blood.V108.11.1838.1838

Published: 2006

Journal Articles

Contribution of T-Cell Reconstitution during the Early Phase after Cord Blood Transplantation to Favorable Clinical Outcomes.

Satoshi Takahashi, MD, Nobukazu Watanabe, MD, Jun Ooi, MD, Akira Tomonari, MD, Kashiya Takasugi, MD, Michihiro Uchiyama, MD, Takaaki Konuma, MD, Muneyoshi Futami, MD, Yoshinori Yamanishi, MD, Keisuke Takahashi, Arinobu Tojo, MD, Tokiko Nagamura, MD, Tsuneo A. Takahashi, PhD, Takehiko Mori, MD, Shin-ichiro Okamoto, MD, Hiromitsu Nakauchi, MD, Shigetaka Asano, MD

Blood (2004) 104 (11): 2227.

https://doi.org/10.1182/blood.V104.11.2227.2227

Published: 2004

NARROW

A Mouse Homolog of Mutant Wasp Responsible for X-Linked Neutropenia Causes Reduced Myeloid Progenitor Activity but Rather Increased Neutrophil Compartment in Bone Marrow

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Evaluation of Oncolytic Viral Therapy Combined with or without Artificial Immunoadjuvant Cell Therapy in Immunocompetent Mouse Tumor Models

A Novel Mutant Wasp in X-Linked Neutropenia Partially Recapitulates Defective Neutrophil Production through Its Expression in WASP-Deficient NB4 Cells

Feasibility of a Cell-Based Oncolytic Virotherapy Targeting Bone Marrow Lesions of Multiple Myeloma

The G-CSF Receptor Requires Gab2-Mediated Recruitment of the Tyrosine Phosphatase Shp2 to Promote Lyn-Dependent Proliferation.

RNAi-Mediated Silencing of p190Bcr-Abl Inactivates Stat5 and Cooperates with Imatinib Mesylate and 17-Allylamino-17-Demetoxygeldanamycin in Selective Killing of p190Bcr-Abl-Expressing Leukemia Cells.

ShRNA Targeting p190BCR-ABL Successfully Eliminates Ph-ALL Cells with or without ABL Kinase Domain Mutation.

Contribution of T-Cell Reconstitution during the Early Phase after Cord Blood Transplantation to Favorable Clinical Outcomes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only